Loading...
Market
Which competitor will Elanco outperform by the end of 2024 following Zenrelia™ approval?
2
Resolution / Starting Odds
Elanco outperforms Zoetis • 25%
Elanco outperforms Merck Animal Health • 25%
Elanco outperforms Boehringer Ingelheim • 25%
Elanco underperforms all three • 25%
Publicly available stock market data from sources like NASDAQ or Yahoo Finance
Story
FDA Approves Elanco's Zenrelia™ for Dogs, Shares Up 2%
Sep 19, 2024, 07:18 PM
The U.S. Food and Drug Administration (FDA) has approved Elanco Animal Health's new skin disease treatment for dogs, Zenrelia™ (ilunocitinib tablets). This approval marks a significant advancement in canine dermatology, offering an effective and safe solution for treating skin conditions in dogs. The announcement has positively impacted Elanco's market performance, with the company's shares rising by 2% in afternoon trade.
View original story
Similar markets
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Outperforms all major competitors • 25%
Performs similarly to major competitors • 25%
Underperforms compared to some competitors • 25%
Underperforms all major competitors • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Humalog • 25%
Yes • 50%
No • 50%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Other • 25%
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
